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Practice patterns in transitioning patients
from chronic kidney disease to dialysis: a
survey of United States nephrologists
Mary C. Mallappallil1* , Steven Fishbane2, Rimda Wanchoo2, Edgar Lerma3, Andrea Roche-Recinos1 and Moro Salifu1

Abstract
Background: There are no guidelines for transitioning patients from chronic kidney disease stage 5 to hemodialysis.
We conducted this study to determine if there are uniform patterns in how nephrologists transition patients to dialysis.
Methods: We designed an electronic survey with 39 questions and sent it to a database of practicing nephrologists at
the National Kidney Foundation. Factors that were important for transitioning a patient to hemodialysis were
evaluated, including medication changes on dialysis initiation, dry weight and dialysis prescription.
Results: 160 US Nephrologists replied to the survey; 18% (29/160) of the responses were completed via social
media sites. Prior to dialysis, 74% (118/160), prescribed furosemide and 67% (107/160) used furosemide with
metolazone. Once dialysis started, only 46% (74/160) of the responders continued patients on diuretics daily.
Hypertension medications prescribed in dialysis were calcium channel blockers 69% (112/160), beta blockers 36%
(58/160), angiotensin converting enzyme inhibitor 32% (53/160), angiotensin receptor blocker 29% (46/160) and
diuretics 25% (42/160). Once dialysis started, 68% (109/160) routinely changed medications. Most, 67% (107/160)
ordered patients to avoid anti-hypertensive medications on dialysis days to allow for ultrafiltration. Dry weight
was determined in the first week by 29% (46/160) and in the first month by 53% (85/160). Most, 59% (94/160) felt
that multiple causes lead to hypertension. Most nephrologists would prescribe small dialyzers and a shorter
period of time for the first dialysis session.
Conclusion: The transition period to chronic hemodialysis has variations in practice patterns and may benefit
from further studies to optimize clinical practice.
Keywords: Blood pressure, Chronic kidney disease, Diuretic, Hemodialysis, Medication reconciliation, Nephrologist

Background
According to the United States Renal Data System
(USRDS), at the end of 2013 there were 661,648 prevalent patients with End Stage Renal Disease (ESRD); the
unadjusted prevalence was 2034 per million in the U.S.
population [1]. The first year after the initiation of
hemodialysis (HD) is associated with increased mortality.
The first 90 days has the highest risk which may be related
to multiple causes [2]. Patterns from the Dialysis Outcomes
and Practice Study reported the causes for mortality as
cardiovascular disease (CVD), followed by withdrawal
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from dialysis; other factors include older age, catheter
vascular access issues, albumin < 3.5 g/dL, phosphorus
< 3.5 mg/dL, cancer and congestive heart failure (CHF)
[3]. There is limited information about the practices related
to the initiation of HD, which requires many clinical
decisions and most of the literature is focused on the
timing of initiation of HD.
Major contributors to CVD morbidity include hypertension and volume overload. There is little information
about the ideal blood pressure (BP) in HD patients due
to exclusion of this population in clinical trials; for
example the trial of intensive versus standard blood
pressure control, with a total of 9361 participants, of
which 2646 had early chronic kidney disease (CKD)
had no subjects who were on HD at the start of the
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study [4]. At present, the ideal blood pressure in a HD
patients remains unclear and without defined BP targets
[5–7] [https://www.kidney.org/sites/default/files/KDOQIClinical-Practice-Guideline-Hemodialysis-Update_PublicReview-Draft-FINAL_20150204.pdf] [8].
Multiple therapies including the attaining the correct
dry weight, fluid and sodium restriction and medications to
achieve BP control have been suggested [9–12]. Benefits of
loop diuretics in HD patients include lower inter-dialytic
weight gain, a lower odds of hyperkalemia, decrease in all
cause and CVD mortality [13]. The benefits of renin angiotensin (RAS) blockade for CVD risk reduction is known,
however, the data among HD patients is less certain [14]. A
risk of combining both ACEI and ARB in HD that has been
reported is an increase in both thirst and inter-dialytic fluid
gain, while the variable risk of hyperkalemia was noted
when RAS blockage was used [15–17]. Given the diverse
findings, it is not surprising that a recent study noted
that anti-hypertensive (anti-HTN) medications may be
under-utilized in patients- once HD is initiated [18]. As
there is no universally accepted technique to determine
dry weight, the imprecise technique of altering the
ultrafiltration goal aided by BP is used to attain volume
control [19]. In the transition period it is unclear when
the first dry weight should be determined.
The literature about the initial HD prescription with a
shorter duration, lower blood flow and a smaller dialyzer
to avoid disequilibrium is limited and comes from animal
studies and case reports due to the difficulty of conducting
such a trial in humans [20–22].
There is no uniform approach to adjust BP medications,
diuretics or dry weight when a patient is started on HD.
There is also no clear consensus regarding details on the
initiation, the length of time of the first treatment blood
flow and dialyzer to be used in HD. This study is designed
to understand practice patterns in nephrologists with the
goal of filling in the knowledge gaps in this area.

Methods
We designed an electronic survey with 39 questions and
sent it to a United States database of practicing nephrologists at the National Kidney Foundation (NKF). The survey
was developed after a comprehensive literature search of
the PubMed database on decisions about medication
adjustments in early HD, initial HD prescription, volume
and BP control in the HD treatment, failed to show clear
evidence on clinical practice patterns. A data abstraction
instrument with 39 questions in 7 domains including
demographic, BP medication adjustment including ACE-I
and ARB use, diuretic use, first HD prescription, access use,
other modality use and presence of an ESRD educator was
created. The questionnaire was validated prior to being sent
out in a pilot test to a panel of 15 practicing nephrologist
from multiple sites, including national experts in the field
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of transitioning patients from CKD to HD. The survey was
modified based on the response process from this panel to
ensure clarity of the questions.
The anonymous questionnaire is shown in Additional file 1
which is in the supplementary material. Institutional Review
Board (IRB) approval was obtained from SUNY Downstate
at Brooklyn. The survey was sent out via secured hyperlink
(www.surveymonkey.com) twice by the NKF to its
membership. An information sheet which explained the
survey rationale and author contact information was
attached to the questionnaire. Request to do the survey
were posted on Facebook and Twitter. The survey was a
voluntary without any remuneration for participation.
The collected data was kept anonymous and aggregate
data was analyzed using descriptive statistics, avoiding
duplicate responses. Responses were in the form of
single best choice; comparative situations and ranking.
The sample frame was practicing US nephrologists and
the response rate (< 5%) was in the range of other
nephrology surveys [23]. No data was collected from
the non-responders. Responses were collected between
March 2015 and March 2016.
Statistical analysis

The survey was conducted using Surveymonkey. All
responses were via its secure link and all responses
were available on its site as both individual anonymous
and aggregate data. Electronic mail manager ensured no
duplication of the survey from individuals. The survey had
binary questions (more than/less than; yes/no) in addition
to ranking scales (preferred choice with ranking 1 being
the highest). The electronic questionnaire had multiple
scroll-down pages that were easy to read with clear font.
The survey had some questions where multiple options
could be selected resulting in cumulative response rates
exceeding 100%. Other questions had options to select
from alternative mutually exclusive choices. Ranking
was used to determine what was degrees of importance
including “yes, likely, unlikely, no” and on a numeral
scale to determine position of preferences. These questions
enabled the computer algorithm to assign a unique weight
for each choice. When data was summarized with descriptive statistics, it was described as weighted averages and as
percentages.

Results
Participants and their settings: Surveys were sent to
members in the US-NKF nephrologist’s database in March
2015 and repeated again. The response rate was 160/ 5000
and responses were collected until March 2016. Eighteen
percent (28/160) of the surveys that were completed, were
in response to request placed on social media (Facebook
and Twitter). Among the 160 responses, most 60% (96/160)
were in practice for more than 10 years. Social media
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platforms were used by 28 nephrologist of whom 75%
(19/28) were in practice for more than 10 years.
Among responders, 50% (80/160) started patients on
HD in both inpatient or outpatient settings, where as
29% (46/160) reported starting patients on dialysis in the
out-patient setting alone and 21% (34/160) reported that
first dialysis in the hospital setting alone.
Diuretic use

Asked about diuretic use the majority of the respondents
74% (118/160) reported using furosemide in CKD5 and
67% (107/160) reported using a combination of furosemide
with metolazone. Multiple selections were allowed and
choices were not mutually exclusive. Once HD had
been started, 46% (74/160) of respondents continued to
prescribe diuretics daily; 31% (50/160) ordered their
use on non-HD days only and 22% (35/160) stopped
the use of diuretics altogether. When asked about the use
of spironolactone, 48% (77/160) of respondents reported
that it was continued even after the initiation of HD
(Table 1).
Anti-hypertensive effectiveness

Participants were asked about the most effective medications to control BP control in HD and the timing of the
medications. The majority 69% (110/160) of the respondents considered calcium channel blockers to be the
most effective; 34% (54/160) of them prescribed nifedipine
and 35% (56/160) of them administered amlodipine. Beta
blockers were reported to be effective by 36% (58/160);
ACEI by 32% (51/160); ARB by 29% (46/160) and diuretics
by 25% (40/160) (Table 2).
When asked what percentage of their HD patients are
using ACEI/ARBs, 51% (82/160) of the respondents
reported between30 to 60% (Table 3). When asked what
factors were important in controlling BP in a patient on
HD, 49% (78/160) responded that it was volume, 18%
(29/160) replied that pre-existing HTN was important
and 9% (13/160) replied that cardiac function was most
important; the majority 59% (94/160) agreed it was a
combination of factors that allow BP control.
Table 1 Use of diuretics when transitioning a patient to
hemodialysis
Diuretic use in CKD5

118

Furosemide with metolazone

107

Calcium Channel blocker
Amlodipine

N = 160
110
56

Nifedipine

54

Beta blockers

58

Angiotensin Converting Enzyme Inhibitor

51

Angiotensin Receptor Blocker

46

Diuretics

40

Avoid BP medications prior to hemodialysis
to allow for ultrafiltration

107

BP = blood pressure

Timing of medication

Most of the respondents 68% (109/160) changed the
dose of BP medications after the initiation of HD. In
addition, 67% (107/160) of the respondents reported
asking patients not to take their BP medications on the
morning of HD to allow for greater ultrafiltration. When
asked about details regarding the dose adjustments of the
BP medications on a daily basis, 41% (66/160) of the
respondents were more likely to tell the patients to take
the BP medications daily and 41% (66/160) were more
likely to tell the patient to take them on non-dialysis
days only. Most of the respondents 58% (93/160) would
not tell their newly started HD patients to stop the BP
medications completely.
Regarding discontinuation of anti-hypertensive medications, in choosing between beta blockers and calcium
channel blockers, 72% (115/160) would first stop calcium
channel blockers. As far as medications being dialyzed
out, 68% (109/160) or respondents would not change beta
blockers to those were not dialyzed. After starting dialysis,
most responders 69% (110/160) reported they had patients
on once a day or long acting calcium channel blockers.
First month of dialysis and changes

Ninety two percent of survey participants (147/160)
replied that they would use a low blood flow setting
(less than 300 ml/minute) for the first dialysis session and
48% (77/160) would use a smaller than usual dialyzer,

Table 3 Use of Angiotensin Converting Enzyme Inhibitors and
Angiotensin Receptor Blockers in Hemodialysis
Responses about ACEI and ARB on hemodialysis

Diuretic use in CKD5-D
74

Non-HD day use

50

Stop diuretic when HD started

35

CKD 5 = chronic kidney disease stage 5, HD = hemodialysis

Blood pressure (BP) medication

Total N = 160

Furosemide

Daily use once HD started

Table 2 Use of BP medications when transitioning a patient to
hemodialysis

N = 160

Report that between 30 and 60% of patients on ACEI or ARB

82

CKD5 would not stop ACE I or ARB

98

Would not change ACEI to one that is not dialyzed out

123

Would not stop ACEI or ARB despite hyperkalemia

104
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while 94% (150/160) prescribed less time for the first
session. In addition, 64% (102/160) would use a lower than
usual dialysate flow rate. In general, 79% (126/160) of
respondents would dialyze the patient for less than a full
dialysis session at the first session (Table 4).
In the first month of chronic dialysis, a large part of
those surveyed, 88% (141/160), felt that ultrafiltration
alone would help control BP and they would not use
additional medications to the existing regiment. Fifty
three percent (85/160) of responders would set the dry
weight in the first month, 29% (46/160) in the first week
and about 18% (29/160) would set the dry weight on the
first day and adjust as needed.
Medication review was done one every month by the
greater part of the participants 78% (125/160), every week
by 12% (19/160) and as needed only by few 9% (15/160).
One option in non-adherent patients is to administer
medications in dialysis. The larger part of those surveyed
85% (136/160) would not use BP medications while their
patients were in HD even in the setting of non-adherence.
Access use in early dialysis

In response to the time interval between access creation
and maturation, 53% (85/160) of responders felt it was
usually between 6 and 12 weeks, 34% (54/160) found it
to be more than 12 weeks and 13% (21/160) noted that
accesses would mature in less than 6 weeks.The question
of how many angioplasties were considered to be acceptable before creating a new access had a distribution of
responses: 27% (43/160) thought 3 angioplasties should be
the most allowed, 25% (40/160) replied 2, 23% (37/160)
replied more than 4, 18% (29/160) replied that only one
angioplasty should be done before a new access was
needed and 7% (11/160) thought 4 could be acceptable
before primary access failure needing the creation of a
new access. Forty two percent (67/160) of nephrologists
responding to the survey felt that 30–60% of patients
started HD with a permanent access in place, 31% (50/160)
Table 4 Decision and changes made once hemodialysis was
started
Decisions and changes made once HD started

N = 160

Less than usual time for first HD

150

Lower than usual blood flow for first dialysis

147

First anti-HTN medication to be stopped: calcium
channel blocker

115

Changed BP medication or doses once HD started

109

Continued use of diuretics in HD daily

74

Continued use of daily anti-hypertensives

66

Medication review done every month

125

Selected choice that HTN in HD is caused by multiple factors

94

HD = hemodialysis, ACEI = Angiotensin Converting Enzyme
Inhibitors, HTN = hypertension

felt it was between 10 and 30% that started HD with a permanent access and 21% (34/160) replied that it was more
than 60% of HD patients that started HD with the required
access. Nine responders avoided this question.
Other renal replacement therapy options

In the process of transitioning patients and other options
being considered 44% (70/160) of responders felt that
more than 50% of their incident HD patients who were
eligible for transplant were listed for kidney transplantation. Eight percent of nephrologist who replied to the
survey noted than < 10% of their CKD patients got a
pre-emptive kidney transplantation. Asked about peritoneal
dialysis (PD) as the first choice in those who were eligible,
44% (70/160) of respondents felt that only 10–50% started
with their first choice even eligible to do so. The majority
65% (104/160) replied they had access to a patient
educator.

Discussion
The first 90 days after starting HD is a period of high
mortality with CVD as the leading cause of death.
Hypertension, left ventricular hypertrophy, electrolyte
and electrocardiographic abnormalities in dialysis are
known to be contribute to the high mortality in this
population [24–28]. The transition period has changes
in these risk factors notably: BP, electrolytes, ultrafiltration
and medications. The gap in knowledge about optimal BP
control in HD in the new HD patient makes clinical
care complex during this period. As there is no unified
approach for BP control in new HD patients this survey
of practicing nephrologists to determine common practices
is relevant.
The survey found the most effective medication in HD
for BP control to be calcium channel blockers, followed
by beta blockers, based on studies showing benefits of
these agents in selected dialysis populations [29–32].
The effectiveness of calcium channel blocker in HD may
be partly explained by the observation that the high inflow
of calcium from the dialysate into the blood stream
during HD may increase BP and would suggest that
blocking the vascular smooth muscle would help better
control BP [33].
The increasing use of ACE I and beta blockers in dialysis
patients with comorbid conditions like congestive heart
failure and the benefits thereof were noted in the literature
and was reflected in the common use of these medications
in this study [34]. For example studies of USRDS data
noted that beta blockers use had increased 75% in those
with previous acute myocardial infarctions and ACEI and
ARB use had increased in those with CHF [35, 36]. In the
survey, once on HD, the majority did not change ACEI
(like enalapril, one third of which is dialyzed out) to one
that would not be removed by dialysis, despite existing
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guidelines to do so. Most patients were instructed to
avoid BP medications on HD days to allow for ultrafiltration- a common practice in HD, which is the opposite of
recommendations that suggest daily nocturnal dosing
of anti-hypertensive medications [37]. Avoidance of BP
medications on HD days is not supported by literature;
in one study of intra-dialytic BP variation it was noted
that ultrafiltration volume resulted in greater change in
systolic BP while the amount of anti-hypertensives was
not associated with systolic BP changes [38]. A balanced
option to minimize the risk of hypotension and cramping
with HD while controlling BP is to keep patients on once
a day nocturnal BP medications [39].
Responders noted that on HD initiation, anti-hypertensive
medications were routinely changed, however uncertainty
about BP fluctuations in the first month resulted in 88%
using ultrafiltration alone to control BP without adding
further medications. As dialysis vintage progressed
there was a greater degree of comfort using anti-HTN
medications.
The study found a majority of nephrologists prescribed
diuretics in CKD 5 prior to HD but once HD was started
less than half continued diuretics on a daily basis. In HD
there is some benefit from diuretics; the underutilization
noted in our study is consistent with known literature,
possibly due to misperceived marginal benefits of the
diuretics and possibly an attempt to lower the pill burden
in new dialysis patients [40]. Further, with decreasing
residual renal function, the effectiveness of diuretics
decreases, while the risk of adverse drug events continues
to be present. A practice of twice a week hemodialysis
supplemented with diuretics may be of special benefit in
the elderly with limited mobility to get to the HD unit. A
recent study suggests that lower ultrafiltration in combination with a large dose diuretic use may help slow the
decline in endogenous renal function for the first two
years after dialysis initiation [41]. The majority of respondents felt that multiple causes lead to HTN in HD not just
increased volume. Medication review was reported to be
done monthly by the majority of nephrologists.
Volume appears to significantly contribute to HTN in HD
and subsequently contribute to CVD mortality [19, 42, 43].
In the survey, nephrologists reported that dry weight was
determined by between the first week and the first month.
To combat inter-dialytic fluid gains, most ultrafiltration
goals are determined clinically; only a minority of HD
centers use bio-impedance routinely to determine fluid
status according to a recent United Kingdom survey [44].
Most nephrologists would prescribe small dialyzers
with a shorter period of time for the first dialysis session.
The responses to questions about timing of access placement, maturity and salvage revealed the large majority
considered access placement maturity needing at least
3 months, however the number of angioplasties to
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salvage the fistula showed a wide variation. Starting
chronic dialysis is a major life sty le change for patients
with many aspects that need improvement [45]. The
presence of a dedicated dialysis educator may help make
this transition smoother and 65% of the responders noted
that their dialysis unit had an educator in their unit.
The limitations of our study includes the emphasis on
the CVD risk in the transition period, while parameters
like nutrition and phosphate control were not included [46].
The other limitation was the low response rate, but this
similar to other nephrology studies in this group [47, 48]. As
there is limited data about how nephrologists transition
patients to dialysis, even with the above limitations, this
study is helpful.

Conclusion
In summary, transitioning patients from CKD5 to HD
continues to remain challenging in terms of mortality, BP
control, medication use, medication reconciliation and the
time to determine initial dry weight of the patient. There
is a lack of consistent patterns in how patients are transitioned from CKD5 to HD, which may be expected in the
absence of strong data. Clinical trials are needed to help
transitioning patients from CKD 5 to HD to help improve
patient outcomes.
Additional file
Additional file 1: Survey sample: transitioning patients from CKD to
dialysis. (DOCX 16 kb)
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